Early access
Sign in
Enrolling by invitationNo phase

Rubidium-82 scan to find parathyroid adenomas in primary hyperparathyroidism

Looks at how parathyroid adenomas take up rubidium-82 on PET/CT scans.

Key facts

Who runs it
Matthieu Pelletier-Galarneau, MD MSc
Where
Canada2 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Parathyroid Adenoma Detection With Rubidium-82 Imaging
Status
Enrolling by invitation
People taking part
20 people, planned
Started
Nov 2026
Expected to end
Sept 2028
Type of study
Observational
Treatments tested
  • PET/CT imaging with rubidium-82
Record updated
27 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with primary hyperparathyroidism and a known parathyroid adenoma (a benign growth in a parathyroid gland). It tests whether rubidium-82 PET/CT scans can show these growths.

Age
18 years or older
Sex
All sexes
Disease stage
Primary hyperparathyroidism shown by blood tests, with a parathyroid adenoma. People with normal calcium levels (normocalcemic form) cannot join.
Earlier treatment
A parathyroid adenoma must already have been seen on an earlier 18F-fluorocholine scan.
Biomarker or test result
Blood test results showing primary hyperparathyroidism.

Main reasons for not taking part

  • Primary hyperparathyroidism with normal calcium levels
  • Pregnancy or breastfeeding
  • Fear of closed spaces, or not able to go through the scans
  • Other illness or condition that the study doctor thinks would affect taking part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age ≥ 18y
  • Ability to undergo imaging logistics
  • Ability to provide informed consent
  • Biochemical evidence of primary hyperparathyroidism
  • Documented parathyroid adenoma on prior 18F-fluorocholine imaging

Who cannot take part

  • Any other history, condition, therapy, or uncontrolled intercurrent illness, which could in the opinion of the investigator affect compliance with study requirements or which would make the participant unsuitable for this study
  • Normocalcemic primary hyperparathyroidism
  • Breastfeeding or pregnancy
  • Claustrophobia or inability to undergo imaging logistics

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Assess the uptake of rubidium-82 in parathyroid adenomas.

Treatments tested

  • PET/CT imaging with rubidium-82

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Parathyroid Adenoma Detection With Rubidium Chloride Imaging: A Proof-of-Concept Study
Plain-language title
Rubidium-82 scan to find parathyroid adenomas in primary hyperparathyroidismGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
27 October 2026